In short: Collins owns it and Eisman: "I own it too." A converted vegetable greenhouse in California — "the low-cost provider," ~$90–100/lb pro forma. Medical cannabis moved from Schedule I to Schedule III; the prize is exporting (interstate or overseas): "in California they sell it for $200 a pound… in Germany it's 600, 700 bucks a pound," which would mean "50 to 65% EBITDA margins." Timing: "evolving slowly… a 2027 event"; first hemp sold overseas this quarter. A small cap (~$0.8–1B).
Glass House grows cannabis in huge former vegetable greenhouses in California, and it can do so more cheaply than almost anyone. Collins and Eisman both own the stock.
The federal government moved medical cannabis out of the most restricted drug category (where heroin sits) into a much lighter one. The bet is that this eventually lets Glass House sell outside California. Cannabis sells for about $200 a pound in California but $600 to $700 in places like Germany, so exports could make it very profitable. The catch is timing: they expect real progress around 2027, and it is a small company.
44:59These guys basically bought a huge vegetable glass house and gut — and gut it in May and they grow weed. — Yep. The opportunity here is recently last December and then eventually finalized they rescheduled — the government federal government — federal government rescheduled the classification of medical cannabis from schedule one to schedule three.
In short: A cannabis company he owns; premium management interview posted June 24. The rescheduling of medical cannabis to class 3 prompted a move to the NYSE — ticker GLAS begins trading June 30. "I own this stock and this is not meant as a recommendation."
2:10We dropped an interview with the head of investor relations at Glass House Brands, a cannabis company whose stock I own. We moved this episode up because a lot has changed in the world of cannabis over the past few months. All for the better, and we explore it all. Also, the company just announced it will be listed on the New York Stock Exchange because of the rescheduling of medical cannabis to class 3.
In short: A cannabis company he owns; premium management interview posts June 24. The Trump administration reclassifying medical cannabis from Schedule 1 to Schedule 3 "will improve growth and earnings." Educational, not a recommendation.
Glass House Brands is a cannabis grower/seller that Eisman personally owns. His catalyst: the Trump administration is reclassifying medical cannabis from Schedule 1 (the most restricted drug category, alongside heroin) to Schedule 3 — a much lighter classification that, he says, "will improve growth and earnings" for the industry by easing the legal and tax burden.
He's running a premium management interview on June 24, and stresses it's educational, not a recommendation.
1:11Before we get to the wrap, on Premium Wednesday, June 24, we will post an interview with the management of Glass House Brands, a cannabis company. The reclassification by the Trump administration of medical cannabis from a schedule one to a schedule 3 drug will improve growth and earnings. I own the stock and on Wednesday, July 1st, I will share my long positions in my personal portfolio and how I think about managing my investments.
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.